15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Rigel Pharmaceuticals Inc, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $57.00 to $81.00, a moderate spread. The average target of $69.00 sits 84% above the current $37.52. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.22 next quarter toward $4.83 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Rigel Pharmaceuticals Inc.
As of Jul, 3 of 4 firms rate RIGL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RIGL EPS & revenue forecast
EPS · NEXT QUARTER
$1.22
Range $0.95 – $1.62 · 4 analysts · -17% YoY
Next period, 4 analysts expect Rigel Pharmaceuticals Inc to earn $1.22 a share (range $0.95 – $1.62), versus $1.46 a year earlier. Full-year consensus is $2.89, growing to $4.83 the year after.
REVENUE · NEXT QUARTER
$79.2M
Range $72.9M – $84.1M · 4 analysts · +14% YoY
Revenue is expected to reach $79.2M (range $72.9M – $84.1M), +14.1% year-over-year. Full-year consensus is $278.9M, rising to $339.2M next year.
Top analysts covering Rigel Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RIGL.
#1
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$81.00+115.9% to target
Overall win rate
43%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #162
Hold
$15.00-60.0% to target
Overall win rate
38%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$57.00+51.9% to target
Overall win rate
32%
+ Follow
#4
FH
Farzin Haque
Jefferies
Buy
$42.00+11.9% to target
Coverage
—
+ Follow
RIGL stock forecast FAQ
What is RIGL's average 12-month price target?+
The 2 analysts with a live target average $69.00 for Rigel Pharmaceuticals Inc over the next 12 months, ranging from a $81.00 high to a $57.00 low.
Is RIGL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RIGL?+
The Street-high target is $81.00 (Citigroup), and the Street-low is $57.00 (HC Wainwright & Co.). The average of all 2 active targets is $69.00.
How many Wall Street analysts cover RIGL?+
4 analysts have an active rating on Rigel Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering RIGL?+
Among analysts who currently cover RIGL, Yigal Nochomovitz of Citigroup has the strongest overall Quantellect track record (Rank #131). Their current call is Buy with a $81.00 target.
What is Rigel Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $1.22 per share (range $0.95 – $1.62) across 4 analysts. Full-year EPS is projected at $2.89, rising to $4.83 the following year.
How much revenue is Rigel Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $79.2M (range $72.9M – $84.1M). Full-year revenue is projected at $278.9M, growing to $339.2M next year.
Have analysts been upgrading or downgrading RIGL lately?+
As of Jul, 3 of 4 firms rate RIGL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RIGL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
